The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.
The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.
复制标题
DOI：
10.1371/journal.pone.0057604
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Cho WC
中科院分区：
文献类型：
--
作者：
Li SG;Chen HY;Ou-Yang CS;Wang XX;Yang ZJ;Tong Y;Cho WC
许多已发表的研究反映了补充和替代医学的应用越来越多，特别是中草药（CHM）与常规癌症治疗联合使用治疗晚期非小细胞肺癌（NSCLC），但其疗效在很大程度上尚未探索。本研究的目的是评价中药联合常规化疗（CT）治疗晚期非小细胞肺癌的疗效。对11个电子数据库中的出版物进行了广泛检索，纳入了24项试验进行分析。这些研究共入组了2，109例患者，其中1，064例患者参加了CT联合CHM，1，039例患者参加了CT（6例患者退出，未报告入组）。与单纯CT相比，中药联合CT可显著提高1年生存率（RR = 1.36，95% CI = 1.15-1.60，p = 0.0003）。 此外，联合治疗显著增加了即刻肿瘤反应（RR = 1.36，95%CI = 1.19-1.56，p<1.0E−5）和改善了Karnofsky表现评分（KPS）（RR = 2.90，95%CI = 1.62-5.18，p = 0.0003）。 联合治疗可明显减轻Ⅲ ~ Ⅳ级毒性反应患者的恶心呕吐（RR = 0.24，95% CI = 0.12-0.50，p = 0.0001），并可防止Ⅰ ~ Ⅳ级毒性反应患者的血红蛋白和血小板下降（RR = 0.64，95% CI = 0.51-0.80，p<0.0001）。 此外，还确定了NSCLC患者常用的草药。本系统评价表明，中药作为辅助治疗可降低晚期NSCLC患者的CT毒性，延长生存率，提高肿瘤即刻缓解率，并改善KPS。但是，由于纳入的研究中缺乏大规模的随机临床试验，因此需要进一步进行更大规模的试验。
Many published studies reflect the growing application of complementary and alternative medicine, particularly Chinese herbal medicine (CHM) use in combination with conventional cancer therapy for advanced non-small cell lung cancer (NSCLC), but its efficacy remains largely unexplored. The purpose of this study is to evaluate the efficacy of CHM combined with conventional chemotherapy (CT) in the treatment of advanced NSCLC. Publications in 11 electronic databases were extensively searched, and 24 trials were included for analysis. A sum of 2,109 patients was enrolled in these studies, at which 1,064 patients participated in CT combined CHM and 1,039 in CT (six patients dropped out and were not reported the group enrolled). Compared to using CT alone, CHM combined with CT significantly increase one-year survival rate (RR = 1.36, 95% CI = 1.15–1.60, p = 0.0003). Besides, the combined therapy significantly increased immediate tumor response (RR = 1.36, 95% CI = 1.19–1.56, p<1.0E−5) and improved Karnofsky performance score (KPS) (RR = 2.90, 95% CI = 1.62–5.18, p = 0.0003). Combined therapy remarkably reduced the nausea and vomiting at toxicity grade of III–IV (RR = 0.24, 95% CI = 0.12–0.50, p = 0.0001) and prevented the decline of hemoglobin and platelet in patients under CT at toxicity grade of I–IV (RR = 0.64, 95% CI = 0.51–0.80, p<0.0001). Moreover, the herbs that are frequently used in NSCLC patients were identified. This systematic review suggests that CHM as an adjuvant therapy can reduce CT toxicity, prolong survival rate, enhance immediate tumor response, and improve KPS in advanced NSCLC patients. However, due to the lack of large-scale randomized clinical trials in the included studies, further larger scale trials are needed.
登录
查看更多内容
影响因子：
3.4
作者：
Brake, Maria K.;Bartlett, Clark;Taylor, S. Mark
通讯作者：
Taylor, S. Mark
影响因子：
2.4
作者：
Chang, Mun Seog;Kim, Do Rim;Park, Seong Kyu
通讯作者：
Park, Seong Kyu
影响因子：
3.3
作者：
Kato, Harubumi;Tsuboi, Masahiro;Hamada, Chikuma
通讯作者：
Hamada, Chikuma
影响因子：
20.4
作者：
Baggstrom, Maria Q.;Stinchcombe, Thomas E.;Socinski, Mark A.
通讯作者：
Socinski, Mark A.
DOI：
10.3779/j.issn.1009-3419.2008.03.003
发表时间：
2008-06-20
期刊：
Zhongguo fei ai za zhi = Chinese journal of lung cancer
影响因子：
--
作者：
Chen, Yanzhi;Di, Lijun;Li, Pingping
通讯作者：
Li, Pingping